Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Myotonic Dystrophy Type 1 Genetic Testing in Over 30,000 Patients: Does Size Really Matter As We Get Older?

ACMG Annual Clinical Genetics Meeting, 2024

American College of Medical Genetics and Genomics

Toronto, Canada, March 12-16, 2024

Poster presentation: Myotonic Dystrophy Type 1 Genetic Testing in Over 30,000 Patients: Does Size Really Matter As We Get Older?

Authors: Powis Z, Liaquat K, Meservey M, Louie JZ, Batish SD

Specialty: Genetics, Neurology

Related content

Publication
Prevalence of RPGR-Mediated Retinal Dystrophy in an Unselected Cohort of Over 5000 Patients
Publication
Targeted Sequencing and In Vitro Splice Assays Shed Light on ABCA4-Associated Retinopathies Missing Heritability
Conference Presentation
Genetic findings in a large cohort of retinal dystrophy patients: implications for gene-specific treatments and clinical trials
Conference Presentation
Characterization of molecular diagnosis of inherited retinal disease within a large pediatric cohort undergoing comprehensive retinal dystrophy panel next-generation sequencing analysis

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.